Top

Published in:

01-09-2019 | Concise Research Reports

Savings from the EpiPen Authorized Generic: a Retrospective Analysis of Medicaid Data

Authors: Inmaculada Hernandez, PharmD, PhD, William H. Shrank, MD, MSHS, Chester B. Good, MD, MPH, Walid F. Gellad, MD, MPH

Published in: Journal of General Internal Medicine | Issue 9/2019

Excerpt

Authorized generics—generic drugs that are simply relabeled versions of the original brand-name drug—are a mechanism by which manufacturers can voluntarily lower drug prices. Although evidence from the early 2000s suggests that authorized generics lower prices in the presence of other independent generics,¹ the impact of authorized generics in markets with limited competition remains unknown. …

Berndt ER, Mortimer R, Bhattacharjya A, Parece A, Tuttle E. Authorized Generic Drugs, Price Competition, And Consumers’ Welfare. Health Aff (Millwood). 2007;26(3):790–9.CrossRef

Medicaid State Drug Utilization Data. https://data.medicaid.gov/browse?category=State+Drug+Utilization&limitTo=datasets. Accessed 5 March 2019.

Medicaid Drug Rebate Program. https://www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/index.html. Accessed 5 March 2019.

CVS Health Offers Patients Lowest Cash Price in the Market for Generic Epinephrine Auto-injector to Treat Allergic Reactions. 2017; https://cvshealth.com/newsroom/press-releases/cvs-health-offers-patients-lowest-cash-price-market-generic-epinephrine-auto. Accessed 5 March 2019.

US Department of Justice. Office of Public Affairs. Mylan Agrees to Pay $465 Million to Resolve False Claims Act Liability for Underpaying EpiPen Rebates. https://www.justice.gov/opa/pr/mylan-agrees-pay-465-million-resolve-false-claims-act-liability-underpaying-epipen-rebates. Accessed 5 March 2019.

Title: Savings from the EpiPen Authorized Generic: a Retrospective Analysis of Medicaid Data
Authors: Inmaculada Hernandez, PharmD, PhD
William H. Shrank, MD, MSHS
Chester B. Good, MD, MPH
Walid F. Gellad, MD, MPH
Publication date: 01-09-2019
Publisher: Springer US
Published in: Journal of General Internal Medicine / Issue 9/2019
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-019-04989-6

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Savings from the EpiPen Authorized Generic: a Retrospective Analysis of Medicaid Data

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 9/2019

The Association Between Polypharmacy and Physical Function in Older Adults: a Systematic Review

“That Was Pretty Powerful”: a Qualitative Study of What Physicians Learn When Preparing for Their Maintenance-of-Certification Exams

A Budget Impact Analysis of the Collaborative Care Model for Treating Opioid Use Disorder in Primary Care

Capsule Commentary on Bond et al., Real-time Feedback in Pay-for-Performance: Does More Information Lead to Improvement?

“Get Ready and Empowered About Treatment” (GREAT) Study: a Pragmatic Randomized Controlled Trial of Activation in Persons Living with HIV

Patient-Reported Barriers to Completing a Diagnostic Colonoscopy Following Abnormal Fecal Immunochemical Test Among Uninsured Patients

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page